Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 9592

1.

Germline pathogenic variants identified in women with ovarian tumors.

Carter NJ, Marshall ML, Susswein LR, Zorn KK, Hiraki S, Arvai KJ, Torene RI, McGill AK, Yackowski L, Murphy PD, Xu Z, Solomon BD, Klein RT, Hruska KS.

Gynecol Oncol. 2018 Oct 12. pii: S0090-8258(18)31249-6. doi: 10.1016/j.ygyno.2018.09.030. [Epub ahead of print]

PMID:
30322717
2.

Risk of cardiovascular disease in women with BRCA1 and BRCA2 mutations.

Powell CB, Alabaster A, Armstrong MA, Stoller N, Raine-Bennett T.

Gynecol Oncol. 2018 Oct 9. pii: S0090-8258(18)31289-7. doi: 10.1016/j.ygyno.2018.10.010. [Epub ahead of print]

PMID:
30314670
3.

Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study.

Qian F, Wang S, Mitchell J, McGuffog L, Barrowdale D, Leslie G, Oosterwijk JC, Chung WK, Evans DG, Engel C, Kast K, Aalfs CM, Adank MA, Adlard J, Agnarsson BA, Aittomäki K, Alducci E, Andrulis IL, Arun BK, Ausems MGEM, Azzollini J, Barouk-Simonet E, Barwell J, Belotti M, Benitez J, Berger A, Borg A, Bradbury AR, Brunet J, Buys SS, Caldes T, Caligo MA, Campbell I, Caputo SM, Chiquette J, Claes KBM, Margriet Collée J, Couch FJ, Coupier I, Daly MB, Davidson R, Diez O, Domchek SM, Donaldson A, Dorfling CM, Eeles R, Feliubadaló L, Foretova L, Fowler J, Friedman E, Frost D, Ganz PA, Garber J, Garcia-Barberan V, Glendon G, Godwin AK, Gómez Garcia EB, Gronwald J, Hahnen E, Hamann U, Henderson A, Hendricks CB, Hopper JL, Hulick PJ, Imyanitov EN, Isaacs C, Izatt L, Izquierdo Á, Jakubowska A, Kaczmarek K, Kang E, Karlan BY, Kets CM, Kim SW, Kim Z, Kwong A, Laitman Y, Lasset C, Hyuk Lee M, Won Lee J, Lee J, Lester J, Lesueur F, Loud JT, Lubinski J, Mebirouk N, Meijers-Heijboer HEJ, Meindl A, Miller A, Montagna M, Mooij TM, Morrison PJ, Mouret-Fourme E, Nathanson KL, Neuhausen SL, Nevanlinna H, Niederacher D, Nielsen FC, Nussbaum RL, Offit K, Olah E, Ong KR, Ottini L, Park SK, Peterlongo P, Pfeiler G, Phelan CM, Poppe B, Pradhan N, Radice P, Ramus SJ, Rantala J, Robson M, Rodriguez GC, Schmutzler RK, Hutten Selkirk CG, Shah PD, Simard J, Singer CF, Sokolowska J, Stoppa-Lyonnet D, Sutter C, Yen Tan Y, Teixeira RM, Teo SH, Terry MB, Mads T, Marc T, Amanda ET, Katherine MT, Nadine T, van Asperen CJ, van Engelen K, van Rensburg EJ, Wang-Gohrke S, Wappenschmidt B, Weitzel JN, Yannoukakos D; GEMO Study Collaborators; HEBON; EMBRACE, Greene MH, Rookus MA, Easton DF, Chenevix-Trench G, Antoniou AC, Goldgar DE, Olopade OI, Rebbeck TR, Huo D.

J Natl Cancer Inst. 2018 Oct 12. doi: 10.1093/jnci/djy132. [Epub ahead of print]

PMID:
30312457
4.

High patient satisfaction with a simplified BRCA1/2 testing procedure: long-term results of a prospective study.

Nilsson MP, Nilsson ED, Borg Å, Brandberg Y, Silfverberg B, Loman N.

Breast Cancer Res Treat. 2018 Oct 11. doi: 10.1007/s10549-018-5000-y. [Epub ahead of print]

PMID:
30311024
5.

Germline Mutations in ATM and BRCA1/2 Are Associated with Grade Reclassification in Men on Active Surveillance for Prostate Cancer.

Carter HB, Helfand B, Mamawala M, Wu Y, Landis P, Yu H, Wiley K, Na R, Shi Z, Petkewicz J, Shah S, Fantus RJ, Novakovic K, Brendler CB, Zheng SL, Isaacs WB, Xu J.

Eur Urol. 2018 Oct 8. pii: S0302-2838(18)30684-5. doi: 10.1016/j.eururo.2018.09.021. [Epub ahead of print]

PMID:
30309687
6.

Clinical and Genetic Characteristics of BRCA1/2 Mutation in Korean Ovarian Cancer Patients: A Multicenter Study and Literature Review.

Kwon BS, Byun JM, Lee HJ, Jeong DH, Lee TH, Shin KH, Suh DS, Kim KH.

Cancer Res Treat. 2018 Oct 8. doi: 10.4143/crt.2018.312. [Epub ahead of print]

7.

Prevalence of PALB2 Germline Mutations in Early-onset and Familial Breast/Ovarian Cancer Patients from Pakistan.

Rashid MU, Khan FA, Muhammad N, Loya A, Hamann U.

Cancer Res Treat. 2018 Oct 11. doi: 10.4143/crt.2018.356. [Epub ahead of print]

8.

Role of the general practitioner in the care of BRCA1 and BRCA2 mutation carriers: General practitioner and patient perspectives.

Vande Perre P, Toledano D, Corsini C, Escriba E, Laporte M, Bertet H, Yauy K, Toledano A, Galibert V, Baudry K, Clotet L, Million E, Picot MC, Geneviève D, Pujol P.

Mol Genet Genomic Med. 2018 Oct 11. doi: 10.1002/mgg3.464. [Epub ahead of print]

9.

Multigene panel testing beyond BRCA1/2 in breast/ovarian cancer Spanish families and clinical actionability of findings.

Bonache S, Esteban I, Moles-Fernández A, Tenés A, Duran-Lozano L, Montalban G, Bach V, Carrasco E, Gadea N, López-Fernández A, Torres-Esquius S, Mancuso F, Caratú G, Vivancos A, Tuset N, Balmaña J, Gutiérrez-Enríquez S, Diez O.

J Cancer Res Clin Oncol. 2018 Oct 10. doi: 10.1007/s00432-018-2763-9. [Epub ahead of print]

PMID:
30306255
10.

Shu complex SWS1-SWSAP1 promotes early steps in mouse meiotic recombination.

Abreu CM, Prakash R, Romanienko PJ, Roig I, Keeney S, Jasin M.

Nat Commun. 2018 Oct 10;9(1):3961. doi: 10.1038/s41467-018-06384-x.

11.

Molecular profiling of hormone receptor-positive, HER2-negative breast cancers from patients treated with neoadjuvant endocrine therapy in the CARMINA 02 trial (UCBG-0609).

Liang X, Briaux A, Becette V, Benoist C, Boulai A, Chemlali W, Schnitzler A, Baulande S, Rivera S, Mouret-Reynier MA, Bouvet LV, De La Motte Rouge T, Lemonnier J, Lerebours F, Callens C.

J Hematol Oncol. 2018 Oct 11;11(1):124. doi: 10.1186/s13045-018-0670-9.

12.

Familial breast cancer and DNA repair genes: insights into known and novel susceptibility genes from the GENESIS study, and implications for multigene panel testing.

Girard E, Eon-Marchais S, Olaso R, Renault AL, Damiola F, Dondon MG, Barjhoux L, Goidin D, Meyer V, Le Gal D, Beauvallet J, Mebirouk N, Lonjou C, Coignard J, Marcou M, Cavaciuti E, Baulard C, Bihoreau MT, Cohen-Haguenauer O, Leroux D, Penet C, Fert-Ferrer S, Colas C, Frebourg T, Eisinger F, Adenis C, Fajac A, Gladieff L, Tinat J, Floquet A, Chiesa J, Giraud S, Mortemousque I, Soubrier F, Audebert-Bellanger S, Limacher JM, Lasset C, Lejeune-Dumoulin S, Dreyfus H, Bignon YJ, Longy M, Pujol P, Venat-Bouvet L, Bonadona V, Berthet P, Luporsi E, Maugard CM, Noguès C, Delnatte C, Fricker JP, Gesta P, Faivre L, Lortholary A, Buecher B, Caron O, Gauthier-Villars M, Coupier I, Servant N, Boland A, Mazoyer S, Deleuze JF, Stoppa-Lyonnet D, Andrieu N, Lesueur F.

Int J Cancer. 2018 Oct 10. doi: 10.1002/ijc.31921. [Epub ahead of print]

PMID:
30303537
13.

ROS-induced R loops trigger a transcription-coupled but BRCA1/2-independent homologous recombination pathway through CSB.

Teng Y, Yadav T, Duan M, Tan J, Xiang Y, Gao B, Xu J, Liang Z, Liu Y, Nakajima S, Shi Y, Levine AS, Zou L, Lan L.

Nat Commun. 2018 Oct 8;9(1):4115. doi: 10.1038/s41467-018-06586-3.

14.

Gynecological-endocrinological aspects in women carriers of BRCA1/2 gene mutations.

Doren A, Vecchiola A, Aguirre B, Villaseca P.

Climacteric. 2018 Oct 8:1-7. doi: 10.1080/13697137.2018.1514006. [Epub ahead of print]

PMID:
30295091
15.

Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene Defects.

Isaacsson Velho P, Qazi F, Hassan S, Carducci MA, Denmeade SR, Markowski MC, Thorek DL, DeWeese TL, Song DY, Tran PT, Eisenberger MA, Antonarakis ES.

Eur Urol. 2018 Oct 4. pii: S0302-2838(18)30729-2. doi: 10.1016/j.eururo.2018.09.040. [Epub ahead of print]

PMID:
30293905
16.

BRCA mutations: is everything said?

López-Urrutia E, Salazar-Rojas V, Brito-Elías L, Coca-González M, Silva-García J, Sánchez-Marín D, Campos-Parra AD, Pérez-Plasencia C.

Breast Cancer Res Treat. 2018 Oct 6. doi: 10.1007/s10549-018-4986-5. [Epub ahead of print] Review.

PMID:
30293211
17.

Comparative Genomic Profiling of Refractory/Metastatic Penile and non-Penile Cutaneous Squamous Cell Carcinoma: Implications for Selection of Systemic Therapy.

Jacob JM, Ferry EK, Gay LM, Elvin JA, Vergilio J, Ramkissoon S, Severson E, Necchi A, Killian JK, Ali SM, Schrock AB, Liu NW, Chung J, Miller VA, Stephens PJ, Welsh A, Corona RJ, Ross JS, Bratslavsky G.

J Urol. 2018 Oct 3. pii: S0022-5347(18)43962-6. doi: 10.1016/j.juro.2018.09.056. [Epub ahead of print]

PMID:
30291913
18.

Antiparallel Coiled-Coil Interactions Mediate Homodimerization of the DNA Damage Repair Protein, PALB2.

Song F, Li M, Liu G, Gurla S, Daigham N, Xia B, Montelione G, Bunting S.

Biochemistry. 2018 Oct 5. doi: 10.1021/acs.biochem.8b00789. [Epub ahead of print]

PMID:
30289697
19.

Knowledge Regarding and Patterns of Genetic Testing in Patients Newly Diagnosed With Breast Cancer Participating in the iCanDecide Trial.

Gornick MC, Kurian AW, An LC, Fagerlin A, Jagsi R, Katz SJ, Hawley ST.

Cancer. 2018 Oct 5. doi: 10.1002/cncr.31731. [Epub ahead of print]

PMID:
30289174
20.

Targeting Defects in the Cellular DNA Damage Response for the Treatment of Pancreatic Ductal Adenocarcinoma.

Schmitt A, Feldmann G, Zander T, Reinhardt HC.

Oncol Res Treat. 2018;41(10):619-625. doi: 10.1159/000493401. Epub 2018 Sep 28.

PMID:
30286473

Supplemental Content

Loading ...
Support Center